ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended June 30, 2026 after the market closes on Thursday, August 13, 2026.
The Company is planning to host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international).
The live webcast can be accessed at: https://app.webinar.net/EQx8PqBGe36
The live webcast will feature a set of accompanying presentation slides that will subsequently be available in the Investors section of the Company’s website at: https://immucell.com/investors/
A teleconference replay of the conference call will be available through August 21, 2026, by dialing (855) 669-9658 (toll free) or (412) 317-0088 (international) and utilizing replay access code #8659150.
A webcast replay will also be available at: https://app.webinar.net/EQx8PqBGe36
The Company anticipates no change to the preliminary sales results for the quarter ended June 30, 2026 that were disclosed on July 9, 2026. The Company expects to file its Quarterly Report on Form 10-Q on August 13, 2026 after the market closes.
About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense® line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at: http://www.immucell.com/investors.
| Contacts: | Olivier te Boekhorst, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| investor.relations@immucell.com | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| iccc@lythampartners.com |
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
This Once-Hot AI Stock Now Looks Deeply Undervalued
United States